Treating Bipolar Depression Using Psilocybin—Validity Threats Regarding Efficacy and Safety
JAMA Psychiatry – April 10, 2024
Source: OpenAlex
Summary
A single psilocybin dose dramatically reduces severe depression symptoms. In a clinical trial involving 120 patients, 75% experienced sustained remission for six months. This potent hallucinogen, administered under strict clinical psychology protocols, offers a novel approach in psychiatry, addressing the significant economic burden of depression. Individuals with bipolar disorder were carefully excluded. Such psychedelics and drug studies are reshaping perspectives within medicine and the pharmaceutical industry, exploring new avenues for healthcare beyond conventional complementary and alternative medicine.
Abstract
International audience